Discover 486 paid clinical trials in Rhode Island. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Rhode Island offers a variety of research opportunities for healthy individuals looking to volunteer in paid studies and those with specific health conditions alike. Research centers in Providence, Warwick, and Cranston are actively recruiting participants, providing access to advanced treatments and top-tier healthcare.
Filter
1
Filter results
Results: 486
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
for
Endometrial Cancer
Location: Boston MA, Providence RI, Lebanon NH, Quebec,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT06989112
Phase 3, Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
for
Metastatic Malignant Neoplasm in the Lung,
Location: Halifax, Bangor ME, Scarborough ME, Boston MA,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 50
Code: NCT05235165
Phase 3, Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
for
Parkinsons Disease (PD)
Location: Boston MA, Providence RI, New York NY, Burlington VT,
Sponsor: BlueRock Therapeutics
Sex: All
Age: 45 - 70+
Code: NCT06944522
Phase 3, Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
for
Immunoglobulin A Nephropathy (IgAN)
Location: Boston MA, Providence RI, Worcester MA, The Bronx NY,
Sponsor: Biogen
Sex: All
Age: 18+
Code: NCT06935357
Phase 3, Recruiting
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
for
Metastatic Castration-Resistant Prostate Cancer (mCRPC),
Location: Boston MA, Providence RI, New Haven CT, New York NY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03972657
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Halifax, Bangor ME, Scarborough ME, Boston MA,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT04293562
Phase 3, Recruiting
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
for
Cervical Cancer
Location: Scarborough ME, Providence RI, Manchester CT,
Sponsor: GOG Foundation
Sex: Female
Age: 18+
Code: NCT04831580
Recruiting
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for
Malignant Female Reproductive System Neoplasm,
Location: Brewer ME, Augusta ME, Scarborough ME, Providence RI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06126276
Phase 2, Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for
Acute Leukemia of Ambiguous Lineage,
Location: Scarborough ME, Boston MA, Providence RI, Worcester MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 1
Code: NCT06317662
Phase 2, Recruiting
Bucillamine Phase 2 Trial in Patients With Cystinuria
for
Cystinuria
Location: Boston MA, Warwick RI, New York NY, Birmingham AL,
Sponsor: Revive Therapeutics, Ltd.
Sex: All
Age: 18 - 70+
Code: NCT02942420
Phase 2, Recruiting
Strategy for Improving Stroke Treatment Response
for
Ischemic Stroke
Location: Boston MA, Providence RI, Hartford CT, New Haven CT,
Sponsor: Translational Sciences, Inc.
Sex: All
Age: 18+
Code: NCT05948566
Phase 2, Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer